Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 67
Filter
1.
Curr Gastroenterol Rep ; 16(4): 381, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24595618

ABSTRACT

Hepatitis C (HCV) is a leading cause of liver-related complications, and the burden of liver disease is expected to increase. Given the over-representation of HCV-related liver disease in persons born between 1945 and 1965, and the failure of risk-based screening to identify many infected persons, birth cohort screening has been advocated and endorsed by both the Centers for Disease Control and United States Preventive Services Task Force, regardless of the presence of risk factors. Birth cohort testing is more cost-effective than risk-based screening especially when those with more advanced disease are given priority for treatment. Several barriers exist at the patient and provider level that need to be overcome to fully realize the potential benefit of birth cohort screening in reducing HCV-related morbidity and mortality.


Subject(s)
Hepatitis C, Chronic/diagnosis , Mass Screening/methods , Attitude of Health Personnel , Cohort Studies , Cost-Benefit Analysis , Forecasting , Guideline Adherence , Health Services Accessibility , Hepatitis C, Chronic/epidemiology , Hepatitis C, Chronic/therapy , Humans , Mass Screening/economics , Patient Acceptance of Health Care , Prevalence , United States/epidemiology
5.
Clin Transplant ; 27(2): 311-8, 2013.
Article in English | MEDLINE | ID: mdl-23351129

ABSTRACT

Liver transplantation is the optimal treatment for patients with hepatocellular carcinoma (HCC) and cirrhosis. This study was conducted to determine the impact of pre-transplant locoregional therapy (LRT) on HCC and our institution's experience with expansion to United Network of Organ Sharing Region 4 T3 (R4T3) criteria. Two hundred and twenty-five patients with HCC (176 meeting Milan and 49 meeting R4T3 criteria) underwent liver transplantation from 2002 to 2008. Compared with the Milan criteria, HCCs in R4T3 criteria displayed less favorable biological features such as higher median alpha-fetoprotein level (21.9 vs. 8.5 ng/mL, p = 0.01), larger tumor size, larger tumor number, and higher incidence of microvascular invasion (22% vs. 5%, p = 0.002). As a result, patients meeting Milan criteria had better five-yr survival (79% vs. 69%, p = 0.03) and a trend toward lower HCC recurrence rates (5% vs. 13%, p = 0.05). Pre-transplant LRT did not affect post-transplant outcomes in patients meeting Milan criteria but did result in lower three-yr HCC recurrence (7% vs. 75%, p < 0.001) and better three-yr survival (p = 0.02) in patients meeting R4T3 criteria. Tumor biology and pre-transplant LRT are important factors that determine the post-transplant outcomes in patients with HCC who meet R4T3 criteria.


Subject(s)
Carcinoma, Hepatocellular/therapy , Catheter Ablation , Chemoembolization, Therapeutic , Liver Neoplasms/therapy , Liver Transplantation , Neoadjuvant Therapy , Adult , Aged , Antineoplastic Agents/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Carcinoma, Hepatocellular/mortality , Carcinoma, Hepatocellular/pathology , Carcinoma, Hepatocellular/surgery , Female , Follow-Up Studies , Humans , Liver Neoplasms/mortality , Liver Neoplasms/pathology , Liver Neoplasms/surgery , Male , Middle Aged , Neoplasm Invasiveness , Neoplasm Recurrence, Local/epidemiology , Neoplasm Recurrence, Local/prevention & control , Retrospective Studies , Survival Analysis , Treatment Outcome , Tumor Burden
7.
Transpl Int ; 25(8): 825-9, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22643162

ABSTRACT

Because of the unrelenting donor shortage, utilization of all potential liver donors is essential. However, when utilizing marginal donors it is critical to precisely characterize the risks, inform recipients of those risks, and allocate these higher risk organs to appropriate candidates. Towards this goal, we need to determine the safety and potential consequences, if any, of utilizing hepatitis C (HCV) antibody-positive donors in HCV infected recipients. To further characterize HCV antibody-positive donors, we analyzed prospectively collected serum samples from HCV antibody-positive donors transplanted into HCV RNA-positive recipients from 5/1993 to 10/2008 for HCV viral load (Roche Cobas AmpliPrep/Cobas Taqman HCV Assay) and genotype (Siemens Versant 2.0 LiPA HCV 5' UTR/Core Assay). Seventeen of 32 (53%) HCV antibody-positive donors were RNA negative. Fifteen patients received an HCV RNA-positive donor and nine donor-recipient pairs had different genotypes or subtypes for analysis. When genotype 1 competed with a non-1 genotype, it was found in 5/6 recipients. In 2/3 cases of mismatched genotype 1 subtypes, genotype 1a dominated. Kaplan-Meier analysis of patient and graft survival and fibrosis progression did not reveal differences between patients who received an HCV antibody-positive donor that was viremic or aviremic. In conclusion, approximately half of HCV antibody-positive donors were aviremic. Viral dominance in viremic donor-recipient pairs seems virally determined.


Subject(s)
Hepacivirus/genetics , Hepatitis C Antibodies/genetics , Liver/virology , Tissue Donors , Female , Genotype , Graft Survival/genetics , Humans , Kaplan-Meier Estimate , Liver Transplantation/adverse effects , Male , Middle Aged , RNA, Viral/analysis
8.
Liver Transpl ; 18(8): 949-54, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22467602

ABSTRACT

Hepatocellular carcinoma (HCC) is potentially curable with hepatic resection or transplantation. Few patients are eligible for resection, and many face a long wait for donor organ availability for liver transplantation. Here we report the safety and efficacy of stereotactic body radiation therapy (SBRT), the explant pathology findings and survival of patients treated with SBRT as a bridge to transplantation for HCC. From April 2005 to August 2010, 10 patients with 11 HCCs were treated with SBRT as a bridge to transplantation. All patients were evaluated by a liver transplant surgeon before radiosurgery. SBRT was delivered with the CyberKnife robotic radiosurgery system. After SBRT, all patients underwent orthotopic liver transplantation. The tumor response was determined by explant pathology. The median follow-up was 62 months from the time of SBRT. The mean time on the liver transplant wait list was 163 days. The median tumor size was 3.4 cm (range = 2.5-5.5 cm). The median SBRT dose was 51 Gy (range = 33-54 Gy) in 3 fractions. The median time from SBRT to liver transplantation was 113 days (range = 8-794 days). At 5 years, the overall survival rate and the disease-free survival rate were both 100%. Overall, 4 of the 10 patients (40%) experienced acute toxicity. Most toxicities were grade 1, and they included nausea, fatigue, and abdominal discomfort. One patient had grade 2 nausea/vomiting. Explant pathology revealed no viable tumor in 3 of the 11 tumors for a complete response rate of 27%. The remaining 8 tumors decreased or remained stable in size. In conclusion, with a median follow-up over 5 years, we have found that SBRT as a bridge to liver transplantation for HCC is feasible and well tolerated. SBRT for HCC may enable patients to remain on the list for frequently curative transplantation during the wait for organ availability.


Subject(s)
Carcinoma, Hepatocellular/radiotherapy , Radiosurgery/methods , Adult , Aged , Carcinoma, Hepatocellular/therapy , Disease-Free Survival , Dose-Response Relationship, Radiation , Female , Humans , Liver Neoplasms/therapy , Liver Transplantation/methods , Magnetic Resonance Imaging/methods , Male , Middle Aged , Time Factors , Tomography, X-Ray Computed/methods , Treatment Outcome
9.
Clin Liver Dis (Hoboken) ; 1(1): 2-5, 2012 Feb.
Article in English | MEDLINE | ID: mdl-31186836
10.
Hepatology ; 55(5): 1344-55, 2012 May.
Article in English | MEDLINE | ID: mdl-22135116

ABSTRACT

UNLABELLED: Recent research has identified high hepatitis C virus (HCV) prevalence among older U.S. residents who contracted HCV decades ago and may no longer be recognized as high risk. We assessed the cost-effectiveness of screening 100% of U.S. residents born 1946-1970 over 5 years (birth-cohort screening), compared with current risk-based screening, by projecting costs and outcomes of screening over the remaining lifetime of this birth cohort. A Markov model of the natural history of HCV was developed using data synthesized from surveillance data, published literature, expert opinion, and other secondary sources. We assumed eligible patients were treated with pegylated interferon plus ribavirin, with genotype 1 patients receiving a direct-acting antiviral in combination. The target population is U.S. residents born 1946-1970 with no previous HCV diagnosis. Among the estimated 102 million (1.6 million chronically HCV infected) eligible for screening, birth-cohort screening leads to 84,000 fewer cases of decompensated cirrhosis, 46,000 fewer cases of hepatocellular carcinoma, 10,000 fewer liver transplants, and 78,000 fewer HCV-related deaths. Birth-cohort screening leads to higher overall costs than risk-based screening ($80.4 billion versus $53.7 billion), but yields lower costs related to advanced liver disease ($31.2 billion versus $39.8 billion); birth-cohort screening produces an incremental cost-effectiveness ratio (ICER) of $37,700 per quality-adjusted life year gained versus risk-based screening. Sensitivity analyses showed that reducing the time horizon during which health and economic consequences are evaluated increases the ICER; similarly, decreasing the treatment rates and efficacy increases the ICER. Model results were relatively insensitive to other inputs. CONCLUSION: Birth-cohort screening for HCV is likely to provide important health benefits by reducing lifetime cases of advanced liver disease and HCV-related deaths and is cost-effective at conventional willingness-to-pay thresholds.


Subject(s)
Hepacivirus/isolation & purification , Hepatitis C Antibodies/blood , Hepatitis C/diagnosis , Neonatal Screening/economics , Cohort Studies , Cost-Benefit Analysis , DNA, Viral/analysis , Female , Hepatitis C/epidemiology , Humans , Incidence , Infant, Newborn , Male , Markov Chains , Models, Economic , Neonatal Screening/methods , Polymerase Chain Reaction/methods , Quality-Adjusted Life Years , Sensitivity and Specificity , United States
11.
Am Fam Physician ; 84(10): 1149-54, 2011 Nov 15.
Article in English | MEDLINE | ID: mdl-22085669

ABSTRACT

The diagnosis of depression in older patients is often complicated by comorbid conditions, such as cerebrovascular disease or dementia. Tools specific for this age group, such as the Geriatric Depression Scale or the Cornell Scale for Depression in Dementia, may assist in making the diagnosis. Treatment decisions should consider risks associated with medications, such as serotonin syndrome, hyponatremia, falls, fractures, and gastrointestinal bleeding. Older white men with depression are at high risk of suicide. Depression is common after stroke or myocardial infarction, and response to antidepressant treatment has been linked to vascular outcomes. Depression care management is an important adjunct to the use of antidepressant medications. Structured psychotherapy and exercise programs are useful treatments for select patients.


Subject(s)
Depressive Disorder/diagnosis , Aged , Aged, 80 and over , Antidepressive Agents/therapeutic use , Depressive Disorder/therapy , Exercise Therapy , Female , Humans , Male , Psychotherapy , Suicide Prevention
12.
Liver Transpl ; 17(12): 1394-403, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21850690

ABSTRACT

This randomized, prospective, multicenter trial compared the safety and efficacy of steroid-free immunosuppression (IS) to the safety and efficacy of 2 standard IS regimens in patients undergoing transplantation for hepatitis C virus (HCV) infection. The outcome measures were acute cellular rejection (ACR), severe HCV recurrence, and survival. The patients were randomized (1:1:2) to tacrolimus (TAC) and corticosteroids (arm 1; n = 77), mycophenolate mofetil (MMF), TAC, and corticosteroids (arm 2; n = 72), or MMF, TAC, and daclizumab induction with no corticosteroids (arm 3; n = 146). In all, 295 HCV RNA-positive subjects were enrolled. At 2 years, there were no differences in ACR, HCV recurrence (biochemical evidence), patient survival, or graft survival rates. The side effects of IS did not differ, although there was a trend toward less diabetes in the steroid-free group. Liver biopsy samples revealed no significant differences in the proportions of patients in arms 1, 2, and 3 with advanced HCV recurrence (ie, an inflammation grade ≥ 3 and/or a fibrosis stage ≥ 2) in years 1 (48.2%, 50.4%, and 43.0%, respectively) and 2 (69.5%, 75.9%, and 68.1%, respectively). Although we have found that steroid-free IS is safe and effective for liver transplant recipients with chronic HCV, steroid sparing has no clear advantage in comparison with traditional IS.


Subject(s)
Adrenal Cortex Hormones/therapeutic use , Antibodies, Monoclonal, Humanized/therapeutic use , Hepatitis C, Chronic/complications , Immunoglobulin G/therapeutic use , Immunosuppressive Agents/therapeutic use , Liver Failure/surgery , Liver Transplantation/immunology , Mycophenolic Acid/analogs & derivatives , Tacrolimus/therapeutic use , Adrenal Cortex Hormones/adverse effects , Antibodies, Monoclonal, Humanized/adverse effects , Antiviral Agents/therapeutic use , Biopsy , Chi-Square Distribution , Daclizumab , Drug Therapy, Combination , Female , Graft Rejection/immunology , Graft Rejection/prevention & control , Hepacivirus/genetics , Hepatitis C, Chronic/diagnosis , Hepatitis C, Chronic/drug therapy , Hepatitis C, Chronic/mortality , Humans , Immunoglobulin G/adverse effects , Immunosuppressive Agents/adverse effects , Kaplan-Meier Estimate , Liver Failure/diagnosis , Liver Failure/mortality , Liver Failure/virology , Liver Transplantation/mortality , Male , Middle Aged , Mycophenolic Acid/adverse effects , Mycophenolic Acid/therapeutic use , Proportional Hazards Models , Prospective Studies , RNA, Viral/blood , Recurrence , Risk Assessment , Risk Factors , Survival Rate , Tacrolimus/adverse effects , Time Factors , Treatment Outcome , United States
13.
Proc (Bayl Univ Med Cent) ; 24(3): 187-91, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21738288

ABSTRACT

The observation that cyclosporine inhibits HCV replication in vitro has led some programs to use cyclosporine as the calcineurin inhibitor (CNI) of choice after orthotopic liver transplantation (OLT). Previous studies comparing outcomes with different CNIs used small HCV cohorts or had short-term follow-up. We examined patient survival and fibrosis progression in all HCV-infected adult primary OLT recipients from 1995 to 2004 at the Annette C. and Harold C. Simmons Transplant Institute (n = 516). Patients were categorized by their CNI on day 7 post-OLT, and they were excluded if they died before day 14. Patient and donor age, sex, race, and prevalence of cytomegalovirus infection post-OLT were similar in the tacrolimus and cyclosporine patients. As expected, acute cellular rejection and steroid-resistant rejection were less common in tacrolimus-treated patients. Although no difference in 1-year survival was seen, tacrolimus patients (n = 268) had superior 5-year survival compared to cyclosporine patients (n = 248) (75% vs. 67%; P = 0.02). Fibrosis progression was no different between the groups. In our retrospective analysis of 516 post-OLT patients, tacrolimus improved long-term survival compared to cyclosporine in HCV-infected patients, although it did not impact HCV fibrosis progression.

14.
Transplantation ; 92(3): 341-5, 2011 Aug 15.
Article in English | MEDLINE | ID: mdl-21659946

ABSTRACT

BACKGROUND: Because myeloproliferative disorders (MPDs) are a frequent cause of Budd-Chiari syndrome (BCS), treatment directed toward altering platelet production and function may be more rational and effective than anticoagulation after liver transplantation. METHODS: We reviewed data on 25 patients who received liver transplantation for BCS at our institution from 1987 to 2007. Posttransplant antithrombotic treatment was based on the cause of BCS: 17 patients with MPDs received hydroxyurea/aspirin; 5 received warfarin; and 3 (2 whose hypercoagulable disorder was corrected and 1 with sarcoidosis) received no therapy. RESULTS: Both graft survival (88% at 5 years) and patient survival (92% at 5 years) were superior in the BCS group compared with the 2609 patients who received liver transplants for other indications. Vascular complications included three instances of hepatic artery stenosis (NS compared with non-BCS liver recipients), one of portal vein thrombosis (nonsignificant [NS]), and one of portal vein stenosis (NS). All 25 patients underwent multiple liver biopsies with no bleeding complications. CONCLUSIONS: Using hydroxyurea and aspirin to treat patients with BCS caused by an MPD seems to be safe and effective and avoids the risks of anticoagulation with warfarin.


Subject(s)
Budd-Chiari Syndrome/etiology , Budd-Chiari Syndrome/prevention & control , Fibrinolytic Agents/therapeutic use , Liver Transplantation/adverse effects , Platelet Aggregation Inhibitors/therapeutic use , Adolescent , Adult , Anticoagulants/therapeutic use , Aspirin/therapeutic use , Budd-Chiari Syndrome/mortality , Child , Female , Follow-Up Studies , Graft Survival , Hepatic Artery , Humans , Hydroxyurea/therapeutic use , Liver Transplantation/mortality , Male , Middle Aged , Portal Vein , Postoperative Complications/etiology , Postoperative Complications/mortality , Postoperative Complications/prevention & control , Thrombosis/etiology , Thrombosis/mortality , Thrombosis/prevention & control , Warfarin/therapeutic use , Young Adult
15.
Clin Gastroenterol Hepatol ; 9(8): 700-704.e1, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21570483

ABSTRACT

BACKGROUND & AIMS: Many patients with cryptogenic cirrhosis (CC) have other conditions associated with nonalcoholic steatohepatitis (NASH) that put them at risk for complications that preclude orthotopic liver transplantation (OLT). METHODS: We followed all patients with NASH and CC who were evaluated for OLT (n = 218) at Baylor Simmons Transplant Institute between March 2002 and May 2008. Data were compared with those from patients evaluated for OLT because of hepatitis C virus (HCV)-associated cirrhosis (n = 646). RESULTS: Patients with NASH and CC were older, more likely to be female, had a higher body mass index, and a greater prevalence of diabetes and hypertension, compared with patients with HCV-associated cirrhosis, but the 2 groups had similar model for end-stage liver disease (MELD) scores. NASH and CC in patients with MELD scores ≤15 were less likely to progress; these patients were less likely to receive OLT and more likely to die or be taken off the wait list because they were too sick, compared with patients with HCV-associated cirrhosis. The median progression rate among patients with NASH and CC was 1.3 MELD points per year versus 3.2 MELD points per year for the HCV group (P = .003). Among patients with MELD scores >15, there were no differences among groups in percentage that received transplants or rate of MELD score progression. Hepatocellular carcinoma occurred in 2.7% of patients with NASH and CC per year, compared with 4.7% per year among those with HCV-associated cirrhosis. CONCLUSIONS: Patients with NASH and CC and low MELD scores have slower disease progression than patients with HCV-associated cirrhosis and are less likely to receive OLT.


Subject(s)
Fatty Liver/complications , Hepatitis C, Chronic/complications , Hepatitis, Chronic/complications , Liver Cirrhosis/complications , Liver Failure/epidemiology , Liver Failure/surgery , Liver Transplantation , Disease Progression , Fatty Liver/pathology , Female , Follow-Up Studies , Hepatitis C, Chronic/pathology , Hepatitis, Chronic/pathology , Humans , Liver Cirrhosis/pathology , Male , Middle Aged , Non-alcoholic Fatty Liver Disease , Severity of Illness Index
16.
Therap Adv Gastroenterol ; 3(1): 43-53, 2010 Jan.
Article in English | MEDLINE | ID: mdl-21180589

ABSTRACT

We finally stand at the brink of novel, oral, direct-acting antivirals for the treatment of hepatitis C virus (HCV) infection. Basic science research has lead to a greater understanding of the viral life cycle and identified numerous potential targets for therapy. Early compounds were plagued by inconsistent in vivo activity and side effects that led to discontinuation of investigational efforts. However, several agents have now progressed to phase 2 human studies and two protease inhibitors have completed enrolment for their phase 3 clinical trials and look promising. Thus, while it appears that protease inhibitors will likely be the next available drugs for the treatment of HCV infection, the quest for additional therapeutic agents will continue. The future of HCV therapy lies in multidrug cocktails of several agents targeted against a variety of targets. In the near future these agents will be added to the current standard therapy consisting of pegylated interferon and ribavirin; however, the ultimate and probably realistic goal will be to develop multidrug oral regiments to replace the need for interferon.

17.
Clin Gastroenterol Hepatol ; 8(11): 924-33; quiz e117, 2010 Nov.
Article in English | MEDLINE | ID: mdl-20713178

ABSTRACT

Hepatitis C virus (HCV) infections pose a growing challenge to health care systems. Although chronic HCV infection begins as an asymptomatic condition with few short-term effects, it can progress to cirrhosis, hepatic decompensation, hepatocellular carcinoma (HCC), and death. The rate of new HCV infections is decreasing, yet the number of infected people with complications of the disease is increasing. In the United States, people born between 1945 and 1964 (baby boomers) are developing more complications of infection. Men and African Americans have a higher prevalence of HCV infection. Progression of fibrosis can be accelerated by factors such as older age, duration of HCV infection, sex, and alcohol intake. Furthermore, insulin resistance can cause hepatic steatosis and is associated with fibrosis progression and inflammation. If more effective therapies are not adopted for HCV, more than 1 million patients could develop HCV-related cirrhosis, hepatic decompensation, or HCC by 2020, which will impact the US health care system. It is important to recognize the impact of HCV on liver disease progression and apply new therapeutic strategies.


Subject(s)
Carcinoma, Hepatocellular/epidemiology , Hepatitis C, Chronic/diagnosis , Hepatitis C, Chronic/epidemiology , Liver Cirrhosis/epidemiology , Liver Neoplasms/epidemiology , Carcinoma, Hepatocellular/diagnosis , Carcinoma, Hepatocellular/therapy , Hepatitis C, Chronic/complications , Hepatitis C, Chronic/therapy , Humans , Liver Cirrhosis/diagnosis , Liver Cirrhosis/therapy , Liver Neoplasms/diagnosis , Liver Neoplasms/therapy , Male , Prevalence , Risk Factors , United States/epidemiology
18.
Curr Gastroenterol Rep ; 12(1): 1-6, 2010 Feb.
Article in English | MEDLINE | ID: mdl-20425478

ABSTRACT

The Baby Boomer generation is composed of 78 million Americans who are just beginning to reach their retirement years. Most Boomers have at least one chronic health problem, and these significantly increase the expense of providing medical care. Liver disease is the 12th most common cause of death in the United States, representing a relatively small portion of overall healthcare costs compared with cardiovascular disease and malignancy. Nonetheless, hepatitis C and fatty liver disease are more common in the Boomers and may play a more dominant role as they age. As a consequence, primary liver cancer is likely to become more prevalent. As with most chronic illnesses, prevention rather than disease management is likely to have the greatest impact. For those already afflicted by chronic liver disease, recognition and treatment can reduce the incidence of late complications, as was clearly demonstrated with chronic hepatitis B and C. Perhaps obesity is the greatest threat to our future health, and fatty liver disease, although likely preventable, will probably become the disease that fills the waiting rooms of future hepatologists.


Subject(s)
Health Care Costs , Health Expenditures , Liver Diseases/economics , Aged , Aged, 80 and over , Aging , Carcinoma, Hepatocellular/economics , Carcinoma, Hepatocellular/epidemiology , Forecasting , Hepatitis B, Chronic/economics , Hepatitis B, Chronic/epidemiology , Hepatitis C, Chronic/economics , Hepatitis C, Chronic/epidemiology , Humans , Liver Diseases/epidemiology , Liver Diseases, Alcoholic/economics , Liver Diseases, Alcoholic/epidemiology , Liver Neoplasms/economics , Liver Neoplasms/epidemiology , Population Dynamics , United States/epidemiology
19.
Liver Transpl ; 16(4): 431-9, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20373454

ABSTRACT

Nonalcoholic steatohepatitis (NASH) may account for many cases of cryptogenic cirrhosis. If so, then steatosis might recur after liver transplantation. Two thousand fifty-two patients underwent primary liver transplantation for chronic liver disease between 1986 and 2004. Serial liver biopsy samples were assessed for steatosis and fibrosis. Two hundred fifty-seven patients (12%) had a pretransplant diagnosis of cryptogenic cirrhosis (239) or NASH (18). Fatty liver developed in 31% and was more common when the pretransplant diagnosis was NASH (45% at 5 years versus 23% for cryptogenic cirrhosis, P = 0.007). NASH developed in only 4% and occurred exclusively when steatosis had already occurred. Steatosis after liver transplantation was associated with the baseline body weight and body mass index by univariate analyses, but no pretransplant or posttransplant characteristic independently predicted steatosis after liver transplantation because obesity was so common in all groups. Five percent and 10% developed bridging fibrosis or cirrhosis after 5 and 10 years, respectively, and this was more common after NASH (31%) than in those who developed steatosis alone (6%) or had no fat (3%, P = 0.002). One-, 5-, and 10-year survival was the same in patients who underwent transplantation for cryptogenic cirrhosis or NASH (86%, 71%, and 56%) and in patients who underwent transplantation for other indications (86%, 71%, and 53%; not significant), but death was more often due to cardiovascular disease and less likely from recurrent liver disease. In conclusion, fatty liver is common after liver transplantation for cryptogenic cirrhosis or NASH but is twice as common in the latter group; this suggests that some cryptogenic cirrhosis, but perhaps not all, is caused by NASH. Posttransplant NASH is unusual, and steatosis appears to be a prerequisite. Advanced fibrosis is uncommon, and survival is the same as that of patients who undergo transplantation for other causes.


Subject(s)
Fatty Liver/etiology , Fatty Liver/therapy , Fibrosis/therapy , Liver Transplantation/adverse effects , Adult , Aged , Biopsy , Cohort Studies , Constriction, Pathologic , Fatty Liver/complications , Female , Fibrosis/complications , Fibrosis/pathology , Humans , Liver/pathology , Liver Transplantation/methods , Male , Middle Aged , Treatment Outcome
20.
Gastroenterology ; 138(2): 513-21, 521.e1-6, 2010 Feb.
Article in English | MEDLINE | ID: mdl-19861128

ABSTRACT

BACKGROUND & AIMS: The prevalence of chronic hepatitis C (CH-C) remains high and the complications of infection are common. Our goal was to project the future prevalence of CH-C and its complications. METHODS: We developed a multicohort natural history model to overcome limitations of previous models for predicting disease outcomes and benefits of therapy. RESULTS: Prevalence of CH-C peaked in 2001 at 3.6 million. Fibrosis progression was inversely related to age at infection, so cirrhosis and its complications were most common after the age of 60 years, regardless of when infection occurred. The proportion of CH-C with cirrhosis is projected to reach 25% in 2010 and 45% in 2030, although the total number with cirrhosis will peak at 1.0 million (30.5% higher than the current level) in 2020 and then decline. Hepatic decompensation and liver cancer will continue to increase for another 10 to 13 years. Treatment of all infected patients in 2010 could reduce risk of cirrhosis, decompensation, cancer, and liver-related deaths by 16%, 42%, 31%, and 36% by 2020, given current response rates to antiviral therapy. CONCLUSIONS: Prevalence of hepatitis C cirrhosis and its complications will continue to increase through the next decade and will mostly affect those older than 60 years of age. Current treatment patterns will have little effect on these complications, but wider application of antiviral treatment and better responses with new agents could significantly reduce the impact of this disease in coming years.


Subject(s)
Disease Progression , Hepacivirus , Hepatitis C/epidemiology , Hepatitis C/physiopathology , Models, Biological , Age Factors , Aged , Aged, 80 and over , Antiviral Agents/therapeutic use , Cohort Studies , Female , Hepatitis C/drug therapy , Humans , Male , Middle Aged , Prevalence , Reproducibility of Results , Sensitivity and Specificity , Treatment Outcome , United States/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL
...